Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).

Trial Details

NCT ID
NCT05798897
Phase
PHASE1
Sponsor
Marker Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • MT-601
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Denver, Colorado, United States|39.73915,-104.9847
  • Kansas City, Kansas, United States|39.11417,-94.62746
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • All applicable inclusion and exclusion criteria must be met at Screening and at Baseline (re-assessment of eligibility within 14 days prior to grou…
  • Participants are eligible to be included in the study only if all of the following criteria apply and the participant, in the judgement of the Inve…
  • Participant must be ≥ 18 years of age and capable of giving signed informed consent (ICF), which includes compliance with the requirements and rest…
  • Disease Specific:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →